Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Cancer Res. 2021 Mar 25;81(11):2956–2969. doi: 10.1158/0008-5472.CAN-20-3450

Fig. 6. Role of differential NCOA3 levels in UV and melanoma susceptibility.

Fig. 6.

(A) Representative images of immunofluorescence detection of various proteins in NHEM cells transfected with control (pcDNA) or human NCOA3 cDNA plasmids (quantitation provided in Fig. S8A). (B) Representative images of immunofluorescence detection of NCOA3 and γH2AX in NHEM cells transfected with control (pcDNA) or human NCOA3 cDNA plasmids with UVC treatment (quantitation provided in Fig. S8B). (C) Prevalence of the T960T NCOA3 polymorphism in a control population (364 cases) versus a familial melanoma cohort (97 cases) (left panel), and in the European (E; HapMap-CEU) versus Sub-Saharan African populations (S-S A; HapMap-YRI) (right panel). (D) Western analysis of NCOA3 and GAPDH in NHEM cells transfected with control (pcDNA), human T960T NCOA3 polymorphism cDNA (hT960T) or human wild-type NCOA3 cDNA (hNCOA3) plasmids (densitometric values provided were normalized to GAPDH). (E) UVC sensitivity (in triplicate) of NHEM cells transfected with control (pcDNA), human T960T NCOA3 polymorphism cDNA (hT960T) or human wild-type NCOA3 cDNA (hNCOA3) plasmids by cell survival analysis. (F) ELISA assay (in triplicate) of 6-4PP from UVC-exposed NHEM cells transfected with control (pcDNA), human T960T NCOA3 polymorphism cDNA (hT960T) or human wild-type NCOA3 cDNA (hNCOA3) plasmids. (G) ELISA assay (in triplicate) of CPD from UVB-exposed NHEM cells transfected with control (pcDNA), human T960T NCOA3 polymorphism cDNA (hT960T) or human wild-type NCOA3 cDNA (hNCOA3) plasmids. * denotes statistically significant differences compared with control. All scale bars are 20 μm.